AlloVir, Inc. is a high-risk Pharmaceuticals company in the USA that specializes in late clinical-stage cell therapy. The company's ESG score is 31.3. AlloVir focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform creates off-the-shelf VSTs to treat patients with limited options. With a research-focused approach, AlloVir targets 11 viruses, with posoleucel leading in treating six viruses. The company is dedicated to preventing and treating severe viral-associated diseases through VST therapies.